Eli Lilly shares fell as much as 4.1% in premarket trading following a report that competitor Novo Nordisk intends to reduce U.S. prices for its diabetes and weight-loss drugs Ozempic and Wegovy by up to 50%.
According to the report, the monthly price for both medications will be set at $675 starting January 1, 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.